Nasodine Nasal Spray phase 3 clinical trial : Firebrick Pharma completes 82% patient recruitment
Firebrick Pharma, an ASX-listed pharmaceutical company, announced that it has successfully enrolled 160 subjects in the confirmatory phase 3 clinical trial of Nasodine Nasal Spray as a potential treatment for the common cold. This enrollment figure represents approximately 82% of the final recruitment target for the trial. The clinical trial, which commenced in 2022, aims […]